The Centers for Medicare and Medicaid Services (CMS) said that deal is expected to supersede the prices negotiated under the ...

Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 ...

Pharmaceutical companies agreed to cut Medicare prices for 15 drugs after negotiations by the Trump administration, a move ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

What’s making the latest hike in FEHB premium payments even harder to stomach for millions of federal employees is its timing ...

Based on a months-long negotiation process between CMS and the manufacturers of these 15 drugs, the final negotiated prices altogether represent savings of 44% on net spending that Medicare would ...

Medicare will pay an average of 36 percent less for 15 of its most expensive prescription drugs starting in 2027, the U.S.

Next year, average federal employee premium payments in the system are set to jump more than 12%, on top of a 13.5% hike in ...

The prescription drug legislation in the Inflation Reduction Act of 2022 — backed by AARP — directed the Department of Health and Human Services to work with pharmaceutical companies to secure reduced ...

The Trump administration says pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs ...

Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.